The Third SAPA-GP Annual Conference

Theme: Globalization of Pharmaceutical/Biotech R&D
Time: Saturday, June 18, 2005
Location: Montgomery County Community College, Blue Bell, Pennsylvania

Conference Highlights:

A Nobel Prize Laureate in medicine and several senior executives from the major US pharmaceutical companies will present their perspectives on current world drug R&D, with a focus on the challenges, opportunities, and globalization trends in the industry. Since this conference will be held one day prior to BIO2005 (the world's largest annual biotech convention, June 19-22, 2005 in Philadelphia), we have also invited a number of executives and officials from top Chinese pharmaceutical/biotech companies and government agencies. They will share with us the current status of drug R&D and regulatory policies in China and their growing impact on global pharmaceutical/biotech R&D. The conference will be followed by the "Shanghai Zhangjiang Night Dinner Reception" sponsored by Zhangjiang Hi-Tech Park.

Session 1: Current Trends in World Pharmaceutical/Biotech Industry

Keynote Speakers

Anthony Ford-Hutchinson, Ph.D., Executive Vice President, Worldwide Basic Research, Merck Research Laboratories, Merck & Co., Inc.
Baruch S. Blumberg, M.D., Ph.D., Nobel Prize Laureate in Medicine, Senior Advisor to President, Fox Chase Cancer Center
Jose V. Sartarelli, Ph.D., Company Group Chairman, Asia-Pacific/Japan/Latin America, Johnson & Johnson Pharmaceuticals Group
Lance Gordon, Ph.D., CEO, VaxGen, Inc.
Anthony Ford-Hutchinson, Ph.D., Executive Vice President, Worldwide Basic Research, Merck & Co.
Robert R. Ruffolo, Jr., Ph.D., President, Research & Development, Wyeth Pharmaceuticals, Senior Vice President, Wyeth Corporation

Session 2: Global R&D Alliance and Outsourcing

Keynote Speakers

Ling Chen, M.D., Ph.D., Director-General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
Ken Fong, Ph.D., Chairman, Kenson Ventures, Founder of Clontech
George Blumberg, Ph.D., Director, Blumberg Associates Limited, Oxford Centre for Innovation, Oxford, UK
Ling Su, M.D., Ph.D., Director, Medical and International Pharma Development, Shanghai Roche Pharmaceuticals Ltd
Kewen Jin, Ph.D., CEO, Shanghai BioExplorer
Nathan Xin Zhang, M.D., Ph.D., MBA, Chairman and CEO, Sinocro Partners
Bill Guo, Ph.D., CEO and President, Venturepharm Holdings Ltd.
Ge Li, Ph.D., Chairman and CEO, Wuxi PharmaTech Co., Ltd

Session 3: Chinese Biotech/Pharma: Challenges and Opportunities

Keynote Speakers

Mr. Dequan Ren, Deputy Director, China State Food Drug Administration.
Hongguang Wang, Ph.D., Director-General, China National Center for Biotechnology Development, The Ministry of Science and Technology of China
Ming-De Yu, Executive Chairman, China Worldbest Life Industry Co, Executive Chairman, China Pharmaceutical Enterprise Management Association and China Pharmaceutical Enterprise Directors Association
Huacheng Wei, MBA, Chairman, Beijing Pharmaceutical Group Co.
Jingkang Shen, Ph.D., Deputy Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Jing Cheng, Ph.D., CEO and CTO, CapitalBio Corporation
Xian-Ping Lu, Ph.D., Co-Founder, Director, and Chief Scientific Officer, Shenzhen Chipscreen Biosciences
Yin Luo, Ph.D., MBA, President and CEO, Shanghai Genomics, Inc
Yongzheng Hui, Chairmen and President of Shanghai Innovation Center of Traditional Medicine, Former Deputy Minister, The Ministry of Science and Technology of China